Effects of repeated increasing doses of cisplatin as models of acute kidney injury and chronic kidney disease in rats
- PMID: 32936352
- DOI: 10.1007/s00210-020-01976-1
Effects of repeated increasing doses of cisplatin as models of acute kidney injury and chronic kidney disease in rats
Abstract
Cisplatin (CP) is nephrotoxic, and this side effect is used as an animal model for acute kidney injury (AKI). Earlier research has been focused on CP-induced AKI, with relatively little attention being paid to its ability to progress to chronic kidney disease (CKD) on repeated administration. We aimed here to test the dose dependency of its nephrotoxic actions by comparing various physiological, biochemical, molecular, and histopathological indices using repeated increasing doses of CP in rats. Furthermore, we investigated whether these doses of CP would result in the development of CKD. Biochemical, molecular, and histopathological measurements were conducted in plasma, urine, and/or kidneys of rats treated with increasing doses of CP at 1.6, 3.2, and 4.8 mg kg-1 weekly for four consecutive weeks. These doses induced significant and dose-dependent elevations in most of the measured renal indices. These included increased renal fibrosis, as suggested histopathologically and biochemically by the significant increase in transforming growth factor-β1, significant decrease in actin alpha 2, and variable actions of collagen I and IV. CP also dose-dependently increased nuclear factor (erythroid-derived 2)-like 2 and caspase-3. Multiple repeated doses of CP (1.6 to 4.8 mg kg-1) induced multiple episodes of AKI, leading to CKD after the 4th weekly dose and confirmed that this dosage regimen could be used as an experimental animal model of AKI progressing to CKD. These actions were driven by inflammation, oxidative, and nitrosative stress.
Keywords: Acute kidney injury; Animal models; Chronic kidney disease; Cisplatin; Fibrosis.
References
-
- Abdelrahman AM, Al Suleimani Y, Shalaby A, Ashique M, Manoj P, Nemmar A, Ali BH (2019) Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice. Naunyn Schmiedeberg's Arch Pharmacol 392:45–53
-
- Alexakis C, Maxwell P, Bou-Gharios G (2006) Organ-specific collagen expression: implications for renal disease. Nephron Exp Nephrol 102:e71–e75 - PubMed
-
- Ali BH, Ahmed IH (2006) Hormonal replacement therapy in an animal model with chronic renal failure and gonadectomy: biochemical and hematological study. Ren Fail 28:331–335 - PubMed
-
- Ali BH, Abdelrahman AM, Al-Salam S, Sudhadevi M, AlMahruqi AS, Al-Husseni IS, Beegam S, Dhanasekaran S, Nemmar A, Al-Moundhri M (2011) The effect of sildenafil on cisplatin nephrotoxicity in rats. Basic Clin Pharmacol Toxicol 109:300–308 - PubMed
-
- Ali BH, Al Za’abi M, Shalaby A, Manoj P, Waly MI, Yasin J, Fahim M, Nemmar A (2015) The effect of thymoquinone treatment on the combined renal and pulmonary toxicity of cisplatin and diesel exhaust particles. Exp Biol Med (Maywood) 240:1698–1707
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous